UBS Maintains Neutral on Oragenics, Raises Price Target to $39

UBS maintains Oragenics (AMEX:OGEN) with a Neutral and raises the price target from $31 to $39.

Benzinga · 11/15/2019 13:06

UBS maintains Oragenics (AMEX:OGEN) with a Neutral and raises the price target from $31 to $39.